The WHO Programme (World Health Organization) is a specialized agency of the United Nations. The goal of this organization is to “achieve better health for all through prevention and control of diseases.” One way they do this is by tracking adverse events that happen during medical procedures, including pharmacovigilance. Pharmacovigilance is an important part of any healthcare system due to its ability to protect patients from harm or death caused by drugs, vaccines, and other products used in healthcare settings. ICSRs are a type of report that can be submitted on behalf of an individual patient as opposed to a group; these reports are stored in VigiBase which was created by the UMC (United Medical Consortium).
What does icsr stand for?
The individual case study report.
ISO ICSR aims at establishing the same format for the reports on individual cases of suspected side effects in patients due to a medicine across the world. It also is expected to include better information on medicines that might be associated with an adverse drug reaction and on the therapeutic uses of those medicines. In addition, the standard also strengthens personal data protection in the records of ICSRs collected by pharmaceutical companies and regulatory authorities.
This will improve the quality of data collected, and increase the ability to search and analyse them. Regulatory authorities will be able to detect and address safety issues with medicines more quickly, and therefore better protect patients.
The Importance of Individual Case Study Reports (ICSR) to Pharmacovigilance
ICSRs are important because they provide a different perspective than adverse event reports, which can be collected from multiple patients. ICSR is an individual case safety report that includes data on individuals who have had experience with the medical treatments or products we want to know about. These types of cases may not always represent the same information as other studies.
Adverse event reporting
The individual case study report (ICSR) is an adverse event report for an individual patient and is the source of data in pharmacovigilance. The main focus of ICSRs are reports from healthcare providers and patients in member countries of the WHO Programme. A WHO global individual case safety report database (VigiBase) is maintained and developed on behalf of the WHO by the UMC.
One of the fundamental principles of adverse event reporting is the determination of what constitutes an Individual Case Safety Report (ICSR). During the triage phase of a potential adverse event report, it is important to determine if the “four elements” of a valid ICSR are present:
- an identifiable patient
- an identifiable reporter (called the “verbatim”)
- a suspect drug
- an adverse event
What is icsr in pharmacovigilance?
The ICSR (Individual Case Study Report) is the source of data in pharmacovigilance. WHO developed a global individual case safety report database, VigiBase, and it is maintained by UMC on behalf of WHO. In this article we will discuss what an ICSR is and why they are important to the process. One purpose that pharmacovigilance provides to the public is to help understand any possible risk associated with medicines or medical devices that have been approved for use and how they should be used safely and effectively. An ICSR (Individual Case Study Report) is the source of data in pharmaco vigilance process – it helps provide understanding about risks related to drugs/medical devices approved for usage;
VigiBase is the single largest drug safety data repository in the world. Since 1978, the Uppsala Monitoring Centre (UMC; established in Uppsala, Sweden) on behalf of WHO, have been maintaining VigiBase. Vigibase is used to obtain the information about a safety profile of a medicinal product. These data are used by pharmaceutical industries, academic institutions and regulatory authorities for statistical signal detection, updating periodic reports, ICSR comparisons with company databases and studying the reporting patterns. The data is collected from each of its 110 member states. About a hundred thousand ICSRs are added each year.
Although somewhat intuitive, there are a set of criteria within pharmacovigilance that are used to distinguish a serious adverse event from a non-serious one. An adverse event is considered serious if it meets one or more of the following criteria:
- results in death, or is life-threatening
- requires inpatient hospitalization or prolongation of existing hospitalization
- results in persistent or significant disability or incapacity
- results in a congenital anomaly (birth defect)
- or is otherwise “medically significant” (i.e., that it does not meet preceding criteria, but is considered serious because treatment/intervention would be required to prevent one of the preceding criteria.)
ISO ICSR standard
Coding of adverse events
Adverse event coding is the process by which information from an adverse effect reporter, is coded using standardized terminology from a medical coding dictionary, such as MedDRA (the most commonly used medical coding dictionary). The purpose of medical coding is to convert adverse event information into terminology that can be readily identified and analyzed. For instance, Patient 1 may report that they had experienced “a very bad headache that felt like their head was being hit by a hammer” [Verbatim 1] when taking Drug X. Or, Patient 2 may report that they had experienced a “slight, throbbing headache that occurred daily at about two in the afternoon” [Verbatim 2] while taking Drug Y. Neither Verbatim 1 nor Verbatim 2 will exactly match a code in the MedDRA coding dictionary. However, both quotes describe different manifestations of a headache. As a result, in this example both quotes would be coded as PT Headache (PT = Preferred Term in MedDRA).
Safety monitoring of medicines in the European Union (EU)
The European Medicines Agency (EMA) has published a guide to support the implementation of a new international standard for the safety monitoring of medicines in the European Union (EU). The so-called ISO ICSR standard improves the reporting of suspected side effects of medicines in Individual Case Safety Reports (ICSRs). The use of the new international standard has taken effect on 1 July 2016. EMA is herewith closing the circle between ICSR and XEVMPD by using the ISO IDMP´s controlled vocabularies. It requires the use of the new ISO IDMP standards when they become available for use in the EU.
MPID – Medicinal Product Identifier
The interesting part for closing the circle between XEVMPD and ISCR is the so called MPID – Medicinal Product Identifier – also part of IDMP standard ISO 11615 identifying the product with ist entire liefe cycle (development, authorisation, post-Marketing and renewal or withdrawal from the market. Further it is stated that ‘until such a time as the ISO IDMP standards are implemented worldwide the support for free text will be required.
However, when the circle will be closed, then the aim of IDMP to increase the patients´safety will be reached.
EMA´s ICSR Implementation Guide
The new guide developed jointly by EMA and the Heads of Medicines Agencies (HMA) will be of interest to pharmaceutical companies and medicines regulatory authorities in EU Member States and will support them to prepare for the use of the standard. The guide specifically defines the electronic transmission process of ICSRs, the format and content of the ICSR, the business rules for report validation as well as classification and data quality principles. It will also assist software providers and IT developers as pharmacovigilance databases are being developed.